Kyowa Kirin Co., Ltd. · TSE:4151
Kyowa Kirin — Q2 2026 Earnings Presentation
47 slides from Kyowa Kirin's earnings presentation, Sep 16, 2026
Slide 1: Results Presentation Fiscal 2026 Second Quarter
Results Presentation Fiscal 2026 Second Quarter
Slide 2: Delivering Life-changing value to Patients
Delivering Life-changing value to Patients Commitment to Life Luis Miguel Berlanas, Father of Candela, affected by XLH Commitment to Life We remain dedicated to our mission of delivering life-changing value to everyone battling illness, as we continue to push the boundaries of innovative drug discov
Slide 3: Agenda
Agenda 01 Q2 2026 Highlights Chairman Masashi Miyamoto 02 Financial Review President and Chief Executive Officer (CEO) Abdul Mullick 03 Commercial update Chief Medical Officer (CMO) Yoshifumi Torii 04 Business update Chief Financial Officer (CFO) Koji Igarashi 05 R&D update © Kyowa Kirin Co., Ltd. 2
Slide 4: Q2 2026 Highlights (Executive Summary)
Q2 2026 Highlights (Executive Summary) ◼ Dialogue with the Capital Markets ⚫ Topics most frequently raised in capital market dialogues ◼ Q2 Financial Results ⚫ Revenue increased by 14% and Core operating profit by 80% ✓ Driven mainly by higher gross profit from tech-licensing, increased North Americ
Slide 5: Dialogue with the Capital Markets
Dialogue with the Capital Markets Capital market engagement after the launch of the C-suite Executive team C-suite dialogue Investors / Shareholders Executive Topics most frequently raised in capital market dialogues Can KKC sustain its growth trajectory beyond 2030? 1. How is the next-growth pipeli
Slide 6: Dialogue with the Capital Markets
Dialogue with the Capital Markets Topics most frequently raised in capital market dialogues “Key Priorities Under the New C-Suite Executive Team” announced Q1 Reaffirmed that many questions can be addressed by advancing the “Key Priorities Under the New C-Suite Executive Team” announced in Q1 © Kyow
Slide 7: Example of Progress against Key Priorities
Example of Progress against “Key Priorities” “Key Priorities Under the New C-Suite Executive Team” announced Q1 Securing resources to Launched initiatives to optimize procurement advance the pipeline and and outsourcing costs expand existing products, Building a global procurement platform beyond si
Slide 8: Financial Review
Financial Review © Kyowa Kirin Co., Ltd. 7
Slide 9: Summary of FY26 Q2 (YTD) Results
Summary of FY26 Q2（YTD） Results Q2 delivered revenue and profit growth, with strong progress toward the full-year plan supported by favorable FX (Billion JPY / Rounded) FY2025 FY2026 FY2026 Change Progress Jan-Jun Jan-Jun Rev. Plans*3 Revenue 230.7 263.6 +33.0 520.0 51% [Overseas Ratio] [73%] [78%]
Slide 10: YoY Analysis ~Revenue~ by Region
YoY Analysis ~Revenue~ by Region Revenue Increased Driven by North America Growth, Higher Technology Income, and Favorable FX Impact Temporary ・Rocatinlimab upfront deferred revenue FY25 4.0 bn (Billion JPY) factors FY26 9.7 bn（+5.6 bn） FY25 Jan-Jun 230.7 Japan Although Phozevel (+22%), Duvroq (+19%
Slide 11: YoY Analysis ~Revenue~ by Product
YoY Analysis ~Revenue~ by Product Revenue growth driven by Crysvita and Poteligeo, along with increased tech-licensing revenue Temporary Rocatinlimab upfront deferred revenue factors FY25 4.0 bn (Billion JPY) FY26 9.7 bn（+5.6 bn） FY25 Jan-Jun 230.7 Crysvita North America (+17%) delivered strong grow
Slide 12: YoY Analysis ~Core Operating Profit~
YoY Analysis ~Core Operating Profit*1~ Core operating profit up on global products, Tech-licensing income, and reduced rocatinlimab development costs (Billion JPY) FY25 Jan-Jun 36.8 Gross Profit Gross profit increased due to higher revenue. +18.0 The gross profit margin increased by 2 points, from 7
Slide 13: YoY Analysis ~Profit~
YoY Analysis ~Profit~ Profit growth driven by higher core operating profit despite impairment losses and clinical trial closing costs related to rocatinlimab (Billion JPY) FY25 Jan-Jun 6.2 Amortization of intangible assets Increased amortization of sales rights due to the launch of KOMZIFTI Core +29
Slide 14: Commercial Update
Commercial Update Coordinated Actions to Maximize Patient Access to Global Strategic Products © Kyowa Kirin Co., Ltd. 13
Slide 15: Crysvita 2026 Key Actions & Q2 Topics
Crysvita 2026 Key Actions & Q2 Topics 2026 KEY ACTIONS 2026 Q2 TOPICS ◼ NA: ◼ Global: YTD Sales rev. YoY +19%, annual plan progress rate 50% Continue investments in people and operations to support patient identification, customer education, and the evolution of patient support services, contributin
Slide 16: Poteligeo 2026 Key Actions & Q2 Topics
Poteligeo 2026 Key Actions & Q2 Topics 2026 KEY ACTIONS 2026 Q2 TOPICS ◼ Global: Support the Poteligeo franchise in MF/SS through aligned global execution and ◼ Global: YTD Sales rev. YoY +20%, annual plan progress rate 47% continued use of clinical and real-world evidence to reinforce long-term val
Slide 17: KOMZIFTI 2026 Key Actions & Q2 Topics
KOMZIFTI 2026 Key Actions & Q2 Topics KEY ACTIONS IN 2026 2026 Q2 TOPICS ◼ KOMZIFTI’s efficacy, safety profile, and ease of use support its positioning as a ◼ Continued launch momentum including physician adoption and new patient starts competitive option in R/R NPM1-mutated AML, with the potential
Slide 18: Business Update
Business Update © Kyowa Kirin Co., Ltd. 17
Slide 19: Sanford manufacturing facility selected for the FDA PreCheck Pilot Program
Sanford manufacturing facility selected for the FDA PreCheck Pilot Program ◼ Sanford, North Carolina manufacturing facility selected for the FDA’s PreCheck Pilot Program ◼ Selected as one of seven companies from more than 80 applicants ◼ Enables early FDA engagement ahead of the standard application
Slide 20: R&D Update
R&D Update © Kyowa Kirin Co., Ltd. 19
Slide 21: Development Pipeline: News Flow
Development Pipeline: News Flow New information highlighted in orange As of Aug 3, 2026 Product Indication Event Status KOMET-017（P3） Ongoing Already marketed as ziftomenib KOMZIFTITM AML KOMET-007（P1）Presentation at EHA Congress and June 2026 Journal Publication OTL-203 MPS-I (Hurler Syndrome) Regi
Slide 22: Ziftomenib: P1 Study (KOMET-007) Results Summary
Ziftomenib: P1 Study (KOMET-007) Newly Diagnosed AML: 7+3 combination – Study Results Summary EHA2026 Study Enrolled and treated： 99cases As of April 10 , 2026 th Design 49 cases：NPM1-m Median follow-up 17.6 months 50 cases：KMT2A-r Median follow-up 11.0 months Manageable safety profile with minimal
Slide 23: Ziftomenib KOMET-007 Safety
Ziftomenib: P1 Study (KOMET-007) Newly Diagnosed AML: 7+3 combination – Safety EHA2026 Manageable safety profile with minimal additive myelosuppression • Safety profile in combination with intensive chemotherapy was consistent with that reported for 7+3 alone¹ Safety • No new or unexpected AEs were
Slide 24: Ziftomenib KOMET-007 Efficacy
Ziftomenib: P1 Study (KOMET-007) Newly Diagnosed AML: 7+3 combination – Efficacy EHA2026 NPM1-m KMT2A-r All Patients n (%) Deep molecular responses (N=49) (N=50) (N=99) and encouraging durability CRc 47 (96) 45 (90) 92 (93) Efficacy ⚫ CRc CR 46 (94) 41 (82) 87 (88) ⚫ CRc MRD negativity CRh 1 (2) 1 (
Slide 25: Appendix
Appendix © Kyowa Kirin Co., Ltd. 24
Slide 26: Revenue of Major Items
Revenue of Major Items (Units are billion JPY, rounded) FY2025 FY2026 FY2026 YoY Change Key Reason Progress Product Name, etc. Jan-Jun Jan-Jun Rev. Plans* 99.8 118.8 +19.0 (+19%) 235.4 50% Japan 6.1 7.0 +0.9 (+15%) 14.7 48% North Crysvita America 64.0 75.1 +11.1 (+17%) Market Penetration EMEA 28.0 3
Slide 27: Impact on Business Performance
Source: Kyowa Kirin, “Discontinuation of Clinical Trials for Rocatinlimab,” disclosed on March 4, 2026. Impact on Business Performance • Short-term profit increase due to elimination of SG&A and R&D expenses related to rocatinlimab • Certain negative profit impact expected in the medium to long term
Slide 28: Key Priorities Under the New C-Suite Executive Team
Source: Kyowa Kirin, “Results Presentation Fiscal 2026 First Quarter” disclosed on May 7, 2026. Key Priorities Under the New C-Suite Executive Team To realize Life-changing value and achieve the financial targets of “Vision 2030 and beyond : Our Growth Story” we clarify the growth pillars as follows
Slide 29: Change in Core Performance Metrics from FY2026
Source: Kyowa Kirin, “FY2025 Financial Results Briefing,” disclosed on Feb 9, 2026. (Updated 2026 Plans) Change in Core Performance Metrics from FY2026 Background Reviewing performance management post 2021-2025 Mid-term Business Plan, we change core performance metrics anticipating the impact of IFR
Slide 30: Impacts arising from the adoption of IFRS 18
[Ref.] Impacts arising from the adoption of IFRS 18 “Presentation and Disclosure in Financial Statements From the fiscal year ending December 2027, the presentation of our consolidated statement of profit or loss will be revised as outlined below. Ahead of this change, we have updated our performanc
Slide 31: Capital Allocation Policy (2026–2028)
Source: Kyowa Kirin, “Kyowa Kirin Equity Story” disclosed in June 2026. Capital Allocation Policy (2026–2028) While properly allocating the generated cash flow to investments for organic growth and to dividends, we will also allocate cash for future inorganic growth with discipline. Source Allocatio
Slide 32: P/L Impact on EMEA established medicines portfolio
P/L Impact on EMEA established medicines portfolio Before After 2024 2025 2026 Aug 2023 Aug 2023 unrealized 49% of the transfer value £ 66.4M(JPY13.1B) £38.5M (JPY7.7B) *Incl. price adj. diff. for 3 Tostran until Oct 3 brands 1 brand brands transferred last year Product sales IP transfer IP transfer
Slide 33: Key Development Pipeline (1)
Key Development Pipeline (1) As of Aug 3, 2026 Planned Development Number of Disease in development*1 approval year*2 status Market size*3 patients*4 AML ziftomenib TBD P3 (Global) ★★★★ 20K (NPM1-m or KMT2A-r, Newly Diagnosed) Achondroplasia TBD P3 (Japan) ★ 1 in 20K live births KK8398 infigratinib
Slide 34: Key Development Pipeline (2)
Key Development Pipeline (2) As of Aug 3, 2026 Disease in Development*1 Development Status Modality, Technology Used Systemic Lupus Erythematosus KK4277 P1 (Japan/Asia) Antibody, POTELLIGENT® Cutaneous Lupus Erythematosus P1 KK2260 Advanced/Metastatic Solid Tumors (JP: Ongoing, US: Prep) Antibody, R
Slide 35: Key Development Pipeline: Future Plans
Orange: Ongoing Key Development Pipeline: Future Plans Gray: Pre-initiation or Completed As of Aug 3, 2026 Development Product Name Target Disease Phase 2026 2027 2028 ＋ ALL P1a1 (KMT2A-r) KOMET- 0012 P1a1 (non NPM1-m / non-KMT2A-r AML) KOMET- 0073 P1 ziftomenib KOMET- AML 0084 P11 KOMET- 0175 P3 KO
Slide 36: Key Development Pipeline: Future Plans
Key Development Pipeline: Future Plans Orange: Ongoing Gray: Pre-initiation or Completed As of Aug 3, 2026 Development Product Name Target Disease Phase 2026 2027 2028 ＋ nAMD P2 KHK4951 tivozanib eyedrop DME P2 SLE KK4277 P1 P1 study nearly complete. Reviewing results to determine next steps. CLE Ad
Slide 37: Ziftomenib: Assets in focus disease areas
Creating Innovative Life-changing value Assets in focus disease areas Ziftomenib In development for relapsed/refractory and front-line AML with NPM1 mutation, KMT2A rearrangement, and FLT3 mutation Differentiated by deep and durable efficacy, combinability with other agents, safety, and a simple dos
Slide 38: KHK4951: Assets in focus disease areas
Creating Innovative Assets in focus disease areas Strategic Partnering Assets Life-changing value KHK4951 In development for neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) Efficient Pursuing the potential to deliver the first anti-VEGF eye drop treatment for dis
Slide 39: KK2845: Assets in focus disease areas
Creating Innovative Life-changing value Assets in focus disease areas KK2845 Kyowa Kirin’s first ADC in development for relapsed/refractory acute myeloid leukemia (AML) Targeting TIM-3 with the ADC to reach leukemic stem cells and blasts — aiming for a fundamental cure of the disease Galectin-9 (TIM
Slide 40: FX Info
FX Info Period Avg. FX Rate (yen) 2025 2026 2026 YoY Jan-Jun Jan-Jun Rev. Plans* USD 150 157 +7 ¥150 GBP 193 212 +19 ¥205 EUR 162 184 +22 ¥180 FY2026 YTD Q2 FX Impact (vs FY25, billion yen) Revenue Core OP USD +6.9 +3.8 GBP +0.3 -1.0 EUR +4.4 +2.5 FY2026 FX Sensitivity (vs FY26 Rev. Plans, billion y
Slide 41: Ziftomenib ~Kura Oncology Collaboration~
Ziftomenib ~Kura Oncology Collaboration~ US Ex-US ◼ Kura leads Dev. Dev. ◼ Dev. costs 50/50 ◼ Kyowa Kirin leads Dev. ◼ Kura funds Dev. (~2028) Commercial. ◼ Kyowa Kirin sells & books sales ◼ Kura books sales ◼ 50/50 Profit Share Sales Royalties ◼ Kyowa Kirin pays double-digit % sales royalties Suppl
Slide 42: Crysvita ~Ultragenyx Collaboration~
Crysvita ~Ultragenyx Collaboration~ Economic Terms ◼ Kyowa Kirin books sales US･Canada ◼ 50/50 profit share for 5 years post-launch ◼ From Yr 6 (Apr 27, 2023), tiered sales royalties to Ultragenyx (mid-to-high 20s%) ◼ Kyowa Kirin books sales Europe ◼ Sales royalties to Ultragenyx (<10%) ◼ Ultragenyx
Slide 43: Est. Patients
Est. Patients Country/ Disease Region Incidence Prevalence1 Source PTCL Japan, US, EU4+UK 59,000 Clarivate - Decision Resources NK/T-Cell Lymphoma - Epidemiology Report Japan 2,000 MHLW 2017 Patient Survey, by Disease CTCL US 1,500 / year SEER Data (2001-2007) Adults: 5,000 Est. based on incidence;
Slide 44: Abbreviations
Abbreviations AG Authorized Generic Authorized Generic ALL Acute lymphoblastic leukemia Acute Lymphoblastic Leukemia AML Acute Myeloid Leukemia Acute Myeloid Leukemia BS Biosimilar Biosimilar CTCL Cutaneous T-cell Lymphoma Cutaneous T-cell Lymphoma DME Diabetic Macular Edema Diabetic Macular Edema E
Slide 45: Reference Information URL
Reference Information URL Vision 2030 and Beyond: Our Growth Story Kyowa Kirin Equity Story Integrated Report 2025 (February 2026) (June 2026) (May 2026) Click here for the material→ LINK Click here for the material→ LINK Click here for the material→ LINK © Kyowa Kirin Co., Ltd. 44
Slide 46: Forward-looking statements disclaimer
This document contains forward-looking statements regarding the outlook, targets, plans, and other future-related matters of the Company (including its consolidated subsidiaries in Japan and overseas). These statements are based on our reasonable judgments using current information and forecasts but
Slide 47: Contact for Inquiries Regarding This Material
～Contact for Inquiries Regarding This Material～ Kyowa Kirin Co., Ltd. Finance Dep., IR Group +81-3-5205-7206 / ir@kyowakirin.com